Opportunity Information: Apply for RFA HL 12 033
Apply for RFA HL 12 033
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Understanding Mechanisms of Terminal Erythroid Maturation (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.839 Blood Diseases and Resources Research.
- This funding opportunity was created on Sep 2, 2011 and posted on Sep 2, 2011.
- Applicants must submit their applications by Feb 1, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $3,150,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $250,000.00 in funding.
- Eligible applicants include: Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) County governments Special district governments Small businesses For profit organizations other than small businesses State governments City or township governments Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Understanding Mechanisms of Terminal Erythroid Maturation (R01)" (Funding Opportunity Number RFA-HL-12-033) is a National Institutes of Health discretionary research grant designed to push forward hypothesis-driven studies on how erythroid precursor cells complete their final steps of development into fully mature red blood cells. The central focus is the late, or terminal, stages of erythroid maturation, a phase where cells undergo major structural and biochemical changes that ultimately enable effective oxygen transport. The program is looking for projects that dig into the molecular mechanisms controlling these final maturation steps, with the broader goal of clarifying why maturation fails in certain disease settings.
A major motivation behind this funding announcement is the clinical problem of erythropoietin-resistant anemias, where patients do not respond well to erythropoietin (EPO) therapy because the underlying defect is not simply inadequate EPO signaling, but rather a breakdown in late-stage erythroid development itself. By supporting mechanistic research that explains what regulates terminal maturation and what disrupts it, NIH is aiming to help the field uncover new therapeutic targets. In practical terms, the hope is that a better map of the regulatory pathways, genes, proteins, and cellular processes involved in terminal erythroid differentiation will point to intervention strategies that can restore effective red blood cell production even when EPO-based approaches fall short.
This opportunity uses the R01 grant mechanism and falls under the health funding activity category, with CFDA number 93.839 (Blood Diseases and Resources Research). The announcement indicates an estimated total funding amount of $3,150,000 for the program. The award ceiling is listed as $250,000, and there is no cost sharing or matching requirement, which means applicants are not expected to provide non-federal funds to receive an award.
Eligibility is broad across the U.S. research ecosystem. Eligible applicants include public and state-controlled institutions of higher education, private institutions of higher education, nonprofits (including both 501(c)(3) and certain non-501(c)(3) organizations), small businesses, for-profit entities other than small businesses, and a wide range of governmental entities such as state, county, city or township governments, special district governments, and independent school districts. The FOA also explicitly includes several institution types and community-serving organizations, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, tribally controlled colleges and universities (TCCUs), faith-based or community-based organizations, and regional organizations, among others. At the same time, it places clear limits on foreign involvement: non-U.S. entities (foreign institutions) are not eligible to apply, non-U.S. components of U.S. organizations are not eligible, and foreign components (as defined by NIH policy) are not allowed under this announcement.
From a timing standpoint, the opportunity was posted and created on September 2, 2011. The original closing date was February 2, 2012, with a current closing date listed as February 1, 2012, and the archive date is March 2, 2012, meaning the announcement is no longer active for new submissions. The full announcement and related details were provided through the NIH grants website at: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-12-033.html. For technical issues accessing or linking to the announcement, NIH directs applicants to the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
Overall, this FOA centers on basic and translationally relevant biology of red blood cell formation at the final maturation stage, with an emphasis on rigorous, hypothesis-led projects that can reveal actionable molecular control points. The program is designed to support work that moves beyond descriptive observations and instead explains how terminal erythroid maturation is regulated, how it breaks down in disease, and how those insights could lead to new therapies for anemias where standard erythropoietin approaches are ineffective.
Frequently Asked Questions (FAQs)
What is the title and funding opportunity number for this grant?
The opportunity is titled "Understanding Mechanisms of Terminal Erythroid Maturation (R01)" and the Funding Opportunity Number is RFA-HL-12-033.
What agency is offering this grant?
This is a National Institutes of Health (NIH) discretionary research grant opportunity.
What type of grant mechanism is used?
The funding mechanism is an NIH R01 research project grant.
What is the main scientific focus of this FOA?
The FOA focuses on hypothesis-driven research that explains the molecular mechanisms governing the late (terminal) stages of erythroid maturation, when erythroid precursor cells complete their final steps to become fully mature red blood cells.
What does "terminal erythroid maturation" mean in the context of this announcement?
In this FOA, terminal erythroid maturation refers to the late developmental phase in which erythroid precursor cells undergo major structural and biochemical changes required to produce mature red blood cells capable of effective oxygen transport.
Why is NIH interested in funding research on terminal erythroid maturation?
A key motivation is the clinical problem of erythropoietin-resistant anemias. In these conditions, patients do not respond well to erythropoietin (EPO) therapy because the underlying defect is not simply inadequate EPO signaling, but rather failure of late-stage erythroid development. NIH is aiming to clarify what regulates terminal maturation and what disrupts it in disease.
How is this FOA connected to erythropoietin (EPO) therapy resistance?
The FOA highlights that some anemias are EPO-resistant because the breakdown occurs in late-stage erythroid maturation itself. The intent is to support mechanistic research that can reveal why maturation fails and identify pathways that may be targeted to restore red blood cell production beyond standard EPO-based approaches.
What kinds of studies does this FOA prioritize?
The FOA prioritizes rigorous, hypothesis-led projects that move beyond descriptive observations and instead explain how terminal erythroid maturation is regulated at the molecular level, how it breaks down in disease settings, and how these insights could suggest actionable therapeutic targets.
What is the broader goal or expected impact of the research supported by this program?
The broader goal is to build a clearer map of regulatory pathways, genes, proteins, and cellular processes involved in terminal erythroid differentiation, helping identify potential intervention strategies for anemias where EPO therapy is ineffective.
What funding activity category does this opportunity fall under?
The FOA falls under the health funding activity category.
What is the CFDA number for this program?
The CFDA number listed is 93.839, which corresponds to Blood Diseases and Resources Research.
How much total funding is estimated for this program?
The estimated total funding amount listed for the program is $3,150,000.
What is the award ceiling for an individual award?
The award ceiling is listed as $250,000.
Is cost sharing or matching required?
No. The FOA specifies there is no cost sharing or matching requirement, meaning applicants are not expected to contribute non-federal funds as a condition of receiving an award.
Who is eligible to apply?
Eligibility is broad and includes public and state-controlled institutions of higher education, private institutions of higher education, nonprofits (including both 501(c)(3) and certain non-501(c)(3) organizations), small businesses, and for-profit entities other than small businesses. It also includes many U.S. governmental entities such as state, county, city or township governments, special district governments, and independent school districts.
Does the FOA explicitly encourage or include specific institution types?
Yes. The FOA explicitly includes several institution types and community-serving organizations, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, tribally controlled colleges and universities (TCCUs), faith-based or community-based organizations, and regional organizations, among others.
Are foreign institutions eligible to apply?
No. Non-U.S. entities (foreign institutions) are not eligible to apply under this announcement.
Can a U.S. organization apply if part of the work will be done at a non-U.S. component?
No. The FOA states that non-U.S. components of U.S. organizations are not eligible.
Are foreign components allowed under NIH policy for this FOA?
No. The FOA states that foreign components (as defined by NIH policy) are not allowed under this announcement.
When was this opportunity posted?
The opportunity was posted and created on September 2, 2011.
What were the closing dates for submission?
The original closing date was February 2, 2012, and a current closing date is listed as February 1, 2012.
Is this funding opportunity still open?
No. The FOA has an archive date of March 2, 2012, indicating it is no longer active for new submissions.
Where can I find the full funding announcement?
The FOA is available on the NIH grants website at http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-12-033.html.
Who should be contacted for technical issues accessing or linking to the announcement?
For technical issues accessing or linking to the announcement, NIH directs users to contact the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
Does the FOA emphasize basic research, translational research, or both?
Based on the description provided, the FOA centers on basic and translationally relevant biology of red blood cell formation during the final maturation stage, with an emphasis on mechanistic understanding that could inform therapeutic development.
Browse more opportunities from the same category: Health
Next opportunity: ANNOUNCEMENT OF OPPORTUNITY FOR THE EARTH SYSTEM SCIENCE PATHFINDER PROGRAM EARTH VENTURE 2
Previous opportunity: mHealth Tools to Promote Effective PatientProvider Communication, Adherence to Treatment and Self Management of Chronic Diseases In Underserved Populations (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 12 033
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 12 033) also looked into and applied for these:
| Funding Opportunity |
|---|
| Reducing Loss to Follow up after Failure to Pass Newborn Hearing Screening Apply for HRSA 12 047 Funding Number: HRSA 12 047 Agency: Health Resources and Services Administration Category: Health Funding Amount: $250,000 |
| Teaching Health Center Graduate Medical Education (THCGME) Program Apply for HRSA 12 029 Funding Number: HRSA 12 029 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| CDCs Collaboration with Academia to Strengthen Public Health Workforce Capacity Apply for CDC RFA OE12 1201 Funding Number: CDC RFA OE12 1201 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Bright Futures Pediatric Implementation Cooperative Agreement Apply for HRSA 12 068 Funding Number: HRSA 12 068 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| FY12 Announcement of Anticipated Availability of Funds for Family Planning Services Grants (Ohio) Apply for PA FPH 12 011 Funding Number: PA FPH 12 011 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $4,168,578 |
| Immunopathogenesis of HIV/AIDS related Oral Manifestations and Host Immunity (R21) Apply for PA 11 333 Funding Number: PA 11 333 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Immunopathogenesis of HIV/AIDS related Oral Manifestations and Host Immunity (R01) Apply for PA 11 334 Funding Number: PA 11 334 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD) (U01) Apply for RFA AA 12 004 Funding Number: RFA AA 12 004 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD) (U24) Apply for RFA AA 12 005 Funding Number: RFA AA 12 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Affordable Care Act Capital Development Building Capacity Grant Program Apply for HRSA 12 115 Funding Number: HRSA 12 115 Agency: Health Resources and Services Administration Category: Health Funding Amount: $5,000,000 |
| Affordable Care Act Capital Development Immediate Facility Improvements Program Apply for HRSA 12 116 Funding Number: HRSA 12 116 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| NIGMS Centers for HIV/AIDS Related Structural Biology (P50) Apply for RFA GM 12 003 Funding Number: RFA GM 12 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Social Neuroscience and Neuroeconomics of Aging (R21) Apply for PAR 11 336 Funding Number: PAR 11 336 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Social Neuroscience and Neuroeconomics of Aging (R01) Apply for PAR 11 337 Funding Number: PAR 11 337 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| FY11 Replacement Grant for Title X Family Planning Services in Parts of New Hampshire Apply for PA FPH 11 016 Funding Number: PA FPH 11 016 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $1,016,866 |
| Human Heredity and Health in Africa (H3Africa) H3Africa Biorepository Grants. (UH2/UH3) Apply for RFA RM 11 011 Funding Number: RFA RM 11 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Viral Hepatitis Surveillance Apply for CDC RFA PS12 1203 Funding Number: CDC RFA PS12 1203 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,200,000 |
| NIDCR Clinical Trial or Biomarker Clinical Evaluation Study Planning Grant (R34) Apply for PAR 11 338 Funding Number: PAR 11 338 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Clinical Trial Implementation or Biomarker Clinical Evaluation Study Cooperative Agreement (U01) Apply for PAR 11 339 Funding Number: PAR 11 339 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mechanisms Explaining Differences in Depressive and Anxiety Disorders Across Racial/Ethnic Groups (R01) Apply for RFA MH 12 090 Funding Number: RFA MH 12 090 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 12 033", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.